+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Not Verified

Annual Open Grant Program

Alternatives Research and Development Foundation

The mission of the Alternatives Research & Development Foundation (ARDF) is to fund and promote the development, validation, and adoption of non-animal methods in biomedical research, product testing, and education.

KEY INFORMATION

• The deadline for letter of intent (LOI) submission is 11:59 pm (ET) on February 20, 2026

• Applicants will be notified regarding an invitation to submit a full application by March 23, 2026

• The deadline for full applications (by invitation only) is 11:59 (ET) on May 25, 2026

• Applicants will be notified of funding decisions by August 10, 2026

• The preferred project period is September 1, 2026 to August 31, 2027. However, projects may start as late as November 1, 2026. All projects must be completed in one year (from the project start date). The maximum award amount is $50,000 (including indirect costs).

• Only non-profit, tax-exempt (501(c)(3)), non-governmental, educational and/or research institutions, or a non-U.S. equivalent, are eligible to receive Annual Open Grant program funds.

PROPOSALS WILL BE EVALUATED ON:

• The extent to which the project would contribute to reducing or replacing laboratory animals, and

• The scientific merit and feasibility of the proposed project

PROPOSALS WILL NOT BE CONSIDERED FOR PROJECTS THAT:

• Use intact, non-human vertebrate or invertebrate animals (note that this is more expansive than the U.S. regulations or policy regarding animal research and includes all non-human metazoans at all stages of life)

• Use monoclonal antibodies produced by in vivo methods

PREFERENTIAL CONSIDERATION WILL BE GIVEN TO PROPOSALS THAT:

• Are from U.S. institutions or organizations

• Utilize in vitro or in silico methods with human cells or data. However, this program discourages projects that are considered “human subjects research” under the U.S. regulations and require IRB oversight.

AI Based Application Success Predictor

1. Strong Alignment with “3Rs” (Replacement > Reduction > Refinement)

The single most important predictor
Projects must replace or significantly reduce animal use, not just improve it
Highest success: full replacement models (human-based systems)

✔ Examples from funded grants:

Human organoids (heart, brain)
Organ-on-chip systems
Human tissue-based ex vivo models

➡ ARDF explicitly prioritizes projects with “greatest potential to replace and reduce animals”

2. Human-Relevant, Non-Animal Methodology

Strong preference for:
- In vitro (cell-based systems)
- Organoids / organ-on-chip
- In silico models
Avoid:
- Any intact animal use (strict exclusion)

➡ Preference noted for human cell/tissue-based approaches

3. High Scientific Merit + Feasibility

Peer-review driven selection
Two equally weighted components:
- Innovation / novelty
- Feasibility within small budget (~$50K)

➡ Proposals evaluated on:

Scientific merit
Feasibility

📌 Practical predictor:

Projects that are innovative but technically achievable in 1–2 years perform best

4. Clear Near-Term Impact

ARDF prefers translatable outcomes, not purely theoretical work

✔ Strong proposals:

Can replace an existing animal model soon
Provide validated alternative tools or protocols

➡ Key criterion:
“Potential to reduce or replace the use of animals in the near future”

5. Method Development / Validation Focus

ARDF is methods-driven, not disease-driven

✔ Funded categories:

New experimental platforms
Validation of alternative assays
Replacement of animal-derived materials

➡ ARDF funds “development, validation, and adoption of alternative methods”

6. Demonstration of Ethical + Scientific Advantage

Winning proposals clearly show:

Why animal models are inadequate
How the alternative is:
- More human-relevant
- More reproducible
- More ethical

📌 This dual argument (science + ethics) is critical for ARDF

7. Early-Stage / Pilot-Friendly Design

Small grant size → favors:
- Pilot studies
- Proof-of-concept work

📊 Insight:

Funding rate ~21% (moderately competitive)

✔ Predictor:

Clearly defined achievable milestones within limited funding

8. Institutional & Geographic Preference

Open globally BUT:
- Slight preference for U.S.-based institutions

➡ Mentioned in eligibility preferences

9. Interdisciplinary & Technology-Driven Projects

Highly competitive proposals often combine:

Biology + engineering (organ-on-chip)
AI + toxicology (in silico models)
Stem cells + disease modeling

🧪 Patterns from Previously Funded Projects

Common winning themes:

Organoids (heart, brain, lung)
Organ-on-chip systems
Human precision-cut tissue models
Serum-free / animal-free culture systems
Drug testing platforms replacing animal studies

➡ These consistently align with ARDF’s mission to replace animal-based science

⚠️ Common Reasons for Rejection

Any use of animals (automatic disqualification)
Weak link to animal replacement
Purely descriptive/basic science without application
Overly ambitious projects for small budget
Lack of validation plan

🧠 Bottom Line (Key Predictors Ranked)

Direct animal replacement potential (highest weight)
Human-relevant model (organoids, in vitro, in silico)
Feasible, well-designed project
Clear near-term application
Method development/validation focus
Strong ethical + scientific justification

Specialties

Others

Technology Development

Eligibility Requirements

Non-profit, non-governmental, educational and/or research institutions (U.S. or non-U.S.)
Projects cannot use intact, non-human vertebrate or invertebrate animals
Projects can be focused on research, testing, or education alternatives

Sponsor Details

Sponsor Institute/Organizations: Alternatives Research and Development Foundation

Sponsor Type: Corporate/Non-Profit

Address: 801 Old York Road, Suite 218 Jenkintown, PA 19046

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity